07/07/2019
Sepranolone receives FDA IND approval in menstrual migraine
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile. [...]
